Sputum clearance devices to improve symptoms in chronic obstructive pulmonary disease

Conditions

COPD patients who produce sputum regularly Respiratory

Alghamdi SM, Alzahrani A, Alshahrani YM, Al Ruwaithi AA, Aldhahir AM, Alsulayyim AS, Siraj RA, Almansour AH, Alasmari AM, Alqahtani JS, Alanazi AM, Jaishi ST, Allehyani BA, Hopkinson NS.

2023-09-141 citations

10.1136/bmjopen-2023-074849

Oscillatory positive expiratory pressure therapy in COPD (O-COPD): a randomised controlled trial

Saeed M. Alghamdi, Abdullah S Alsulayyim, Ali Alasmari, Keir Philip, Sara Buttery et al. (9 authors)

Thorax2022-08-1023 citations

10.1136/thorax-2022-219077

Interventions

Participants will be randomised to OPEP device (the AcapellaTM) with usual care or usual care alone. Allocation will be by computer-generated list. Active: Taught active cycle of brea

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Current participant inclusion criteria as of 02/03/2020: 1. Adult patients with COPD who frequently produce sputum defined as: (i) every or most days in the last month and a score of >=5/8 on the two CAT cough items 2. Stable treatment for the preceding four weeks Previous participant inclusion criteria: 1. Adult patients with COPD who frequently produce sputum defined as: (i) every or most days in the last month and a score of >=6/8 on the two CAT cough items 2. Stable treatment for the preceding four weeks

Exclusion criteria

Exclusion criteria: 1. Unable to provide informed consent 2. Major condition limiting life expectancy for <3 months 3. Referral for chest physiotherapy in the preceding year 4. Already using an adjunct device for sputum clearance 5. Within 1 month of pulmonary exacerbation 6. Within 1 month of COPD medication change 7. Within 1 month of a pneumothorax

Design outcomes

Primary

Measure	Time frame
Cough symptoms measured using the Leicester cough questionnaire (LCQ) at baseline and 12 weeks	—

Secondary

Measure	Time frame
1. Cough severity measured by Visual Analog Scale (VAS) at baseline and 12 weeks 2. Health status measured by CAT score at baseline and 12 weeks 3. Health status measured using EQ-5D-5L at baseline and 12 weeks 4. Fatigue measured using FACIT score at baseline and 12 weeks 5. Exacerbation rate (number of exacerbations during the 12 weeks of the study) measured using patient diaries at 12 weeks A subset of 32 participants will undergo measurement of cough frequency and sleep movements to determine whether the OPEP device influences cough frequency and sleep efficiency. This will use the Leicester Cough Monitor and the McRoberts MoveMonitor at baseline and 12 weeks	—

Measure

Time frame

1. Cough severity measured by Visual Analog Scale (VAS) at baseline and 12 weeks 2. Health status measured by CAT score at baseline and 12 weeks 3. Health status measured using EQ-5D-5L at baseline and 12 weeks 4. Fatigue measured using FACIT score at baseline and 12 weeks 5. Exacerbation rate (number of exacerbations during the 12 weeks of the study) measured using patient diaries at 12 weeks A subset of 32 participants will undergo measurement of cough frequency and sleep movements to determine whether the OPEP device influences cough frequency and sleep efficiency. This will use the Leicester Cough Monitor and the McRoberts MoveMonitor at baseline and 12 weeks

—

Countries

England, United Kingdom

Contacts

Public ContactSaeed AlGhamdi

s.alghamdi18@imperial.ac.uk+44 (0)20 73518029

Outcome results

None listed